SCHEMBL1717740

SCHEMBL1717740

CC[C@H](NC(=O)C(C(C)=O)c1cccc(C(F)(F)F)c1C(=O)O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KCNA5 P22460 1/20 0.38
CNR2 P34972 1/20 0.38
PLK1 P53350 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
MMP2 P08253 6/20 0.37
MMP3 P08254 4/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365096 0.86 TACR3 (0.43) ALDH1A1KDM4ELMNAHPGDTSHR
SCHEMBL4754247 0.81 SLC6A9 (0.39) MAPK1ALDH1A1MEN1KMT2ASLC6A9
SCHEMBL1719085 0.76 SLC6A9 (0.44) POLBMAPK1ALDH1A1KDM4ELMNA
SCHEMBL3633516 0.75 CYP2D6 (0.49) POLBPLK1PLK3CYP2C9KMT2A
SCHEMBL1366952 0.69 KDM4E (0.51) ALDH1A1KDM4ELMNAHPGDTSHR
SCHEMBL1789777 0.67 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAHPGDTSHR
SCHEMBL28262023 0.67 CTRB1 (0.56) ALDH1A1KDM4ELMNAHPGDTSHR
SCHEMBL12311000 0.67 CTRB1 (0.56) ALDH1A1KDM4ELMNAHPGDTSHR
SCHEMBL1789779 0.67 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAHPGDTSHR
SCHEMBL14521519 0.67 ALDH1A1 (0.58) POLBALDH1A1KDM4ELMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 POLB 3562/4885MAPK1 2750/4885ALDH1A1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.